



The Open Rheumatology Journal Supplementary Material

Content list available at: <https://openrheumatologyjournal.com>



Clinical, Radiologic, and Functional Outcomes Following Methotrexate Withdrawal in Etanercept-Treated Patients with Active Early Rheumatoid Arthritis: A Subanalysis of COMET Year 2 by Week 52 DAS28 Status

Paul Emery¹, Ferdinand Breedveld², Eduardo Campos-Alberto³, Annette E. Szumski⁴ and Tomohiro Hirose^{3*}

¹Leeds Institute of Molecular Medicine, Leeds, United Kingdom

²Leids Universitair Medisch Centrum, Leiden, Netherlands

³Pfizer Japan, Tokyo, Japan

⁴Syneos Health, Princeton, NJ, USA

Article History

Received: September 10, 2020

Revised: March 31, 2021

Accepted: April 15, 2021

Supplementary Table 1. Demographics and Period 1 baseline disease characteristics by week 52 DAS28 response categories and by Period 2 treatment arm.

Characteristic	ETN + MTX/ETN + MTX			ETN + MTX/ETN		
	Remission (n=54)	LDA (Excluding Remission) (n=15)	Non-responder (n=36)	Remission (n=63)	LDA (Excluding Remission)(n=12)	Non-responder (n=28)
Age [median], years (range)	53.0 (23.0–78.0)	63.0 (28.0–81.0)	50.5 (22.0–69.0)	54.0 (18.0–71.0)	58.5 (30.0–69.0)	54.5 (18.0–78.0)
Female, n (%)	28 (52)	14 (93)	33 (92)	45 (71)	8 (67)	24 (86)
Disease duration [median], months (range)	6.0 (3.0–24.0)	6.0 (3.0–24.0)	7.0 (3.0–24.0)	8.0 (3.0–24.0)	7.0 (3.0–12.0)	10.0 (3.0–22.0)
DAS28 [median] (interquartile range)	6.1 (5.5–6.8)	6.8 (5.9–7.3)	6.8 (6.2–7.1)	6.1 (5.8–6.8)	6.1 (5.5–7.0)	6.8 (5.8–7.2)
Painful joints – 28 joint count [median] (interquartile range)	11.0 (6.0–18.0)	16.0 (10.0–20.0)	15.0 (11.0–19.5)	12.0 (8.0–16.0)	11.0 (7.5–15.0)	15.5 (9.0–20.0)
Fatigue [median] (interquartile range)	62.5 (32.5–75.0)	57.0 (53.0–69.0)	66.0 (53.0–81.0)	55.5 (40.0–72.0)	70.5 (34.0–78.0)	72.5 (50.5–85.0)
HAQ-DI, mean (SD)	1.6 (0.6)	2.0 (0.6)	1.8 (0.7)	1.5 (0.7)	1.5 (0.8)	1.9 (0.6)
CDAI, median (interquartile range)	36.0 (26.0–47.0)	40.0 (35.0–53.0)	41.0 (30.0–54.0)	33.0 (28.0–42.5)	35.0 (29.0–43.0)	43.0 (30.5–51.0)
mTSS, median (interquartile range)	1.5 (0.5–4.5)	5.3 (4.0–20.4)	2 (1.0–5.0)	2.5 (0.5–9.5)	3.3 (1.5–24.5)	4.0 (1.5–8.5)

CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score; ETN, Etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, Low Disease Activity; mTSS, modified Total Sharp Score; MTX, Methotrexate; NS, No Significant difference ($P > 0.05$); SD, Standard Deviation.